Get the Stockscreener App
0.5564
4.39%
0.0234
Durect Corp stock is traded at $0.5564, with a volume of 3,438.
It is up +4.39% in the last 24 hours and down -6.96% over the past month.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
See More
Previous Close:
$0.533
Open:
$0.53975
24h Volume:
3,438
Relative Volume:
0.03
Market Cap:
$16.48M
Revenue:
$8.59M
Net Income/Loss:
$-17.07M
P/E Ratio:
-0.9121
EPS:
-0.61
Net Cash Flow:
$-21.90M
1W Performance:
+11.30%
1M Performance:
-6.96%
6M Performance:
-36.19%
1Y Performance:
-66.28%
1-Day Range:
$0.531
$0.559
1-Week Range:
$0.4801
$0.5595
52-Week Range:
$0.4801
$1.84
Durect Corp Stock (DRRX) Company Profile
Name
Durect Corp
Sector
Phone
(408) 777-1417
Address
10240 BUBB ROAD, CUPERTINO, CA
Compare DRRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.531 | 15.52M | 8.59M | -17.07M | -21.90M | -0.61 |
|
HLN
Haleon Plc Adr
|
11.16 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.73 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.14 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-12-20 | Initiated | ROTH Capital | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jan-31-20 | Initiated | B. Riley FBR | Buy |
| Nov-18-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-18 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-20-17 | Reiterated | Laidlaw | Buy |
| Oct-20-17 | Downgrade | Stifel | Buy → Hold |
| Jul-12-17 | Upgrade | Stifel | Hold → Buy |
| Feb-28-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-16 | Initiated | Rodman & Renshaw | Buy |
| May-01-15 | Reiterated | Cantor Fitzgerald | Buy |
| May-01-15 | Reiterated | Stifel | Buy |
| Mar-25-13 | Initiated | Stifel | Buy |
| Nov-01-12 | Downgrade | C.K. Cooper | Buy → Hold |
| Aug-17-12 | Initiated | C.K. Cooper | Buy |
| Jun-23-09 | Initiated | Caris & Company | Buy |
| Mar-26-09 | Initiated | Wedbush Morgan | Hold |
View All
Durect Corp Stock (DRRX) Latest News
Durect Corp stock hits 52-week low at $0.52 amid market challenges - Investing.com Australia
Durect Corp stock hits 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
Durect says on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014 - Reuters
DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com - Defense World
Durect: Q1 Earnings Snapshot - New Haven Register
DURECT (DRRX) Q1 Revenue Surpasses Estimates, Focuses on Phase 3 Trial Funding | DRRX Stock News - GuruFocus
Durect Corp Q1 2025 Earnings: EPS at -$0.13 Misses Estimate, Rev - GuruFocus
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
DURECT (DRRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Durect Corp stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Durect Corp stock hits 52-week low at $0.69 amid market challenges - Investing.com
Form 8-KCurrent report - ADVFN
DURECT Co. (NASDAQ:DRRX) Sees Large Decline in Short Interest - Defense World
DURECT (NASDAQ:DRRX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT (DRRX) to Release Quarterly Earnings on Wednesday - Defense World
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Durect Corp Stock (DRRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.28%
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):